Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Nicotine Addiction Overview | 7 | 1 |
| Therapeutics Development | 8 | 2 |
| Pipeline Products for Nicotine Addiction Overview | 8 | 1 |
| Pipeline Products for Nicotine Addiction Comparative Analysis | 9 | 1 |
| Nicotine Addiction Therapeutics under Development by Companies | 10 | 1 |
| Nicotine Addiction Therapeutics under Investigation by Universities/Institutes | 11 | 1 |
| Nicotine Addiction Pipeline Products Glance | 12 | 2 |
| Clinical Stage Products | 12 | 1 |
| Early Stage Products | 13 | 1 |
| Nicotine Addiction Products under Development by Companies | 14 | 1 |
| Nicotine Addiction Products under Investigation by Universities/Institutes | 15 | 1 |
| Nicotine Addiction Companies Involved in Therapeutics Development | 16 | 8 |
| Addex Therapeutics Ltd | 16 | 1 |
| Astraea Therapeutics, LLC | 17 | 1 |
| Cerecor Inc. | 18 | 1 |
| Chronos Therapeutics Limited | 19 | 1 |
| Embera NeuroTherapeutics, Inc. | 20 | 1 |
| Hager Biosciences, LLC | 21 | 1 |
| Heptares Therapeutics Limited | 22 | 1 |
| Omeros Corporation | 23 | 1 |
| Nicotine Addiction Therapeutics Assessment | 24 | 9 |
| Assessment by Monotherapy Products | 24 | 1 |
| Assessment by Combination Products | 25 | 1 |
| Assessment by Target | 26 | 2 |
| Assessment by Mechanism of Action | 28 | 2 |
| Assessment by Route of Administration | 30 | 1 |
| Assessment by Molecule Type | 31 | 2 |
| Drug Profiles | 33 | 25 |
| (metyrapone + oxazepam) Drug Profile | 33 | 2 |
| ADX-71441 Drug Profile | 35 | 4 |
| AT-1001 Drug Profile | 39 | 1 |
| CERC-501 Drug Profile | 40 | 2 |
| EORA-101 Drug Profile | 42 | 1 |
| OMS-405 Drug Profile | 43 | 1 |
| OMS-527 Drug Profile | 44 | 2 |
| Small Molecule for Nicotine Addiction Drug Profile | 46 | 1 |
| Small Molecule for Psychiatric Disorders Drug Profile | 47 | 1 |
| Small Molecule to Antagonize Orexin 1 for Central Nervous System Disorders Drug Profile | 48 | 1 |
| Small Molecules to Antagonize Alpha-4 Beta-2 Nicotinic Acetylcholine Receptor for CNS Disorders Drug Profile | 49 | 1 |
| Small Molecules to Antagonize CRF-R1 and OREXIN-1 for Nicotine Addiction Drug Profile | 50 | 1 |
| Small Molecules to Inhibit Dopamine Transporter for CNS and Metabolic Disorders Drug Profile | 51 | 1 |
| Small Molecules to Inhibit Dopamine, Serotonin, Norepinephrine Transporters for Central Nervous System Disorders Drug Profile | 52 | 1 |
| URB-694 Drug Profile | 53 | 1 |
| Vaccine for Nicotine Addiction Drug Profile | 54 | 1 |
| Vaccine for Nicotine Addiction Drug Profile | 55 | 1 |
| Vaccine for Nicotine Addiction Drug Profile | 56 | 1 |
| Vaccine for Nicotine Addiction Drug Profile | 57 | 1 |
| Nicotine Addiction Dormant Projects | 58 | 1 |
| Nicotine Addiction Discontinued Products | 59 | 1 |
| Nicotine Addiction Product Development Milestones | 60 | 3 |
| Featured News &Press Releases | 60 | 1 |
| Dec 11, 2015: Publication Reports Human Brain Penetration and Target Engagement of Cerecor s Oral Kappa Opioid Receptor Antagonist, CERC-501 | 60 | 1 |
| Jul 10, 2014: Addex ADX71441 Positive Results in Preclinical Model of Nicotine Addiction | 60 | 1 |
| Mar 19, 2013: Omeros Elucidates Mechanism Of PDE7 Inhibitors In Addiction | 61 | 1 |
| Feb 16, 2012: Molecular Express announces award of STTR Phase I funding from the National Institutes of Health to develop a liposomal nicotine vaccine | 61 | 1 |
| May 05, 2011: Omeros Announces Expansion Of Potential Indications For PDE7 Inhibitors | 62 | 1 |
| Appendix | 63 | 2 |
| Methodology | 63 | 1 |
| Coverage | 63 | 1 |
| Secondary Research | 63 | 1 |
| Primary Research | 63 | 1 |
| Expert Panel Validation | 63 | 1 |
| Contact Us | 63 | 1 |
| Disclaimer | 64 | 1 |